A case report reveals incidental findings of pancreatic cancer using PSMA PET/CT in a recurrent prostate cancer patient, suggesting potential therapeutic options.
Introduction Prostate specific membrane antigen (PSMA) is a type II transmembrane protein overexpressed in the neovasculature of some pancreatic ductal adenocarcinoma (PDAC). PET/CT can detect this expression and has now become an essential tool in this context. However, this antigen can also be expressed by other neoplasms. While this may create diagnostic uncertainty, it could also open therapeutic opportunities. Clinical case Here we describe a case in which a PET/CT performed to restage a patient with prostate adenocarcinoma experiencing biochemical recurrence revealed the coexistence of a PDAC. Literature review A literature review aimed to summarize the bibliographic evidence on the use of this technique in this setting, which is relatively uncommon. Conclusion Prostate-specific membrane antigen can be overexpressed in PDACs. This finding may offer potential for theranostic applications
No takes yet. Share an insight, caveat, or question.
Savelli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: